For many years research workers have been attracted by the idea that some endogenously produced psychotogen might be implicated in the etiology of schizophrenia. Unfortunately, lack of knowledge concerning the neurochemical mechanisms of normal behaviour has deprived investigators of a sound basis on which to plan their strategy, with the result that biochemical research into the condition has been mainly characterized by the accumulation of negative findings and discarded theories. However, recent advances in neurochemistry and in the standardization of psychiatric symptomatology and classification have facilitated the emergence of coherent testable hypotheses. One of these predicts that the abnormal metabolism of methylated indoleamines may be a factor in the genesis of some of the symptoms of schizophrenia (Domino 1975 , Gillin etal. 1976).
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Dimethyltryptamine (DMT) and
Hollister's Criteria The indoleamine hypothesis centres on NNdimethyltryptamine, and its adequacy can best be examined in relation to the criteria which Hollister (1967) decreed should be satisfied before any agent can be considered as a possible endogenous cause of schizophrenia (Table 1) . When injected in single doses to human volunteers DMT does include a short-lasting model psychosis in which some of the symptoms of schizophrenia can be discerned; repeated administration does not lead to a general loss of responsiveness to DMT (Gillin et al. 1976 ). The enzymatic machinery and substrates (tryptamine and Sadenosylmethionine) for the endogenous formation of DMT are present in animal and human tissues (Mandel 1975) . DMT is thus not only the first human hallucinogen for which there is a Table I Criteria for an endogenous hallucinogen causative of schizophrenia (after Hollister 1967) (1) The (Wing et al. 1974 ) showed a general association between the excretion of detectable levels of DMT and psychotic symptoms; the symptoms most closely related to DMT detection were hypomania, sexual and fantastic delusions and auditory hallucinations.
Carpenter and his colleagues (1975) have carried out a similar though smaller study in which they failed to detect DMT more frequently in the urine of 12 acute schizophrenics than in that of 9 normal controls. The only way of resolving the discrepancy between their study and ours was to develop a quantitative rather than a qualitative method of estimating DMT. Such a technique has now been developed with a sensitivity limit of about 20 ng per 24 hour sample of urine, i.e. levels some 25 times lower than could be detected with our original method.
Using the new method we have now studied a further 68 subjects. These consisted of 54 recently admitted psychiatric patients and 14 normal controls. None of the subjects had received any drugs other than benzodiazepines in the two preceding weeks, and the estimations were carried out in ignorance of the subjects' clinical condition. We detected DMT in the urine of all subjects, both patients and controls. The level of excretion ranged from 63 to 4500 ng per 24 hours, and the mean levels were much higher for psychotic patients than for neurotic and normal individuals ( 
